PMID- 30407345
OWN - NLM
STAT- MEDLINE
DCOM- 20181120
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 45
DP  - 2018 Nov
TI  - Tumor necrosis factor-alpha-308 gene promoter polymorphism associates with 
      survival of cancer patients: A meta-analysis.
PG  - e13160
LID - 10.1097/MD.0000000000013160 [doi]
LID - e13160
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is involved in cancer 
      pathogenesis, and TNF-alpha-308G>A, a single-nucleotide polymorphism, is associated 
      with cancer prognosis; however, different studies have reported inconsistent 
      results. This meta-analysis aimed to determine the correlation between 
      TNF-alpha-308G>A polymorphism and the survival of cancer patients. METHODS: PubMed, 
      Web of Science, Embase, Wanfang database, VIP database, and China National 
      Knowledge Infrastructure database were used to obtain articles on association 
      between TNF-alpha-308G>A polymorphism and cancer survival, published until April 
      2018. A meta-analysis was carried out using Stata 12.0 software to determine the 
      pooled hazard ratio (HR) and 95% confidence intervals (95% CI). Furthermore, 
      publication bias was assessed, and sensitivity analysis was performed to validate 
      the analysis. RESULTS: In total, 13 retrospective cohort studies including 2559 
      cancer patients were reviewed to estimate the association between TNF-alpha-308G>A 
      polymorphism and overall survival (OS) of cancer patients. The pooled results 
      suggested that within TNF-alpha-308G>A polymorphism, genotypes GA+AA/GG (HR = 1.39, 
      95% CI: 0.90-2.14, P < .001, I = 78.1%), GA/GG (HR = 1.06, 95% CI: 0.83-1.36, 
      P = .072, I = 53.5%), and AA/AG+GG (HR = 3.28, 95% CI: 0.92-11.72, P = .001, 
      I = 85.9%) were not associated with the OS of cancer patients. However, 
      interestingly, the HR was greater for patients with the AA genotype than for 
      those with the GG genotype, suggesting an association between TNF-alpha-308G>A 
      polymorphism and OS among cancer patients (AA/GG, HR = 2.16, 95% CI: 1.36-3.43, 
      P = .281, I = 21.5%). CONCLUSION: TNF-alpha-308G>A polymorphism affects the OS of 
      cancer patients and is a potential therapeutic target for cancer.
FAU - Yi, Fengshuang
AU  - Yi F
AD  - Medical Research Center.
FAU - Shi, Xinyu
AU  - Shi X
AD  - Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, 
      Capital Medical University, Beijing, China.
FAU - Pei, Xuebin
AU  - Pei X
AD  - Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, 
      Capital Medical University, Beijing, China.
FAU - Wu, Xiuzhi
AU  - Wu X
AD  - Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, 
      Capital Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Neoplasms/*genetics/mortality
MH  - Polymorphism, Single Nucleotide
MH  - Survival Rate
MH  - Tumor Necrosis Factor-alpha/*genetics
PMC - PMC6250438
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/11/09 06:00
MHDA- 2018/11/21 06:00
PMCR- 2018/11/09
CRDT- 2018/11/09 06:00
PHST- 2018/11/09 06:00 [entrez]
PHST- 2018/11/09 06:00 [pubmed]
PHST- 2018/11/21 06:00 [medline]
PHST- 2018/11/09 00:00 [pmc-release]
AID - 00005792-201811090-00068 [pii]
AID - MD-D-18-03052 [pii]
AID - 10.1097/MD.0000000000013160 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Nov;97(45):e13160. doi: 10.1097/MD.0000000000013160.